VPC12249, a lysophosphatidic acid receptor type 1 (LPA1) antagonist, plays a functional role in osteoclast differentiation and bone resorption activity.
TPC-144 is a potent and selective LSD1 inhibitor with a reversible inhibition mechanism. TPC-144 has antitumor activity in several human AML and SCLC cell lines and xenograft models.